Sign In
Buy NBIX
$167.35
+2.24 (+1.36%)
At Close: Jun 04, 2026
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
04:01pm, Monday, 06'th Jan 2025
SAN DIEGO , Jan. 6, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the 43rd Annual J.P. Morgan Healthcare Conference at 8:15 a.m.
Neurocrine price target raised to $182 from $172 at BofA
12:19pm, Friday, 20'th Dec 2024
BofA analyst Tazeen Ahmad raised the firm's price target on Neurocrine to $182 from $172 and keeps a Buy rating on the shares. The firm updated its DCF-based model for finalized Crenessity U.S. prices
CRENESSITY, a First-in-Class Treatment for Classic Congenital Adrenal Hyperplasia (CAH), is now commercially available in the U.S. CAH-trained pharmacists are available 24/7 to support patients with p
Neurocrine Biosciences' Crenessity Approval Sets Stage For Diversified Revenue And Growth
10:11am, Wednesday, 18'th Dec 2024
Neurocrine's Ingrezza is forecasted to generate $2.3 billion in revenue in 2024, cementing its role as the company's primary revenue driver. Crenessity's approval for CAH treatment represents a transf
Neurocrine Wins FDA Approval For Genetic Disorder Drug
07:00pm, Friday, 13'th Dec 2024
Neurocrine Biosciences won Food and Drug Administration approval late Friday for the first new treatment for an adrenal disease in decades. The post Neurocrine Wins FDA Approval For Genetic Disorder D
CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach FDA approval supported by data fr
US FDA approves Neurocrine Biosciences' genetic disorder drug
05:50pm, Friday, 13'th Dec 2024
The U.S. Food and Drug Administration has approved Neurocrine Biosciences' drug to treat a type of genetic disorder, the health regulator's website showed on Friday.
Neurocrine Biosciences to Participate at Investor Conferences in December
04:01pm, Tuesday, 26'th Nov 2024
The 7th Annual Evercore HealthCONx Conference on December 3 Citi's 2024 Global Healthcare Conference on December 4 SAN DIEGO , Nov. 26, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)
Why Neurocrine Biosciences Stock Is Very Attractive At Current Levels
11:02am, Friday, 08'th Nov 2024
Neurocrine Biosciences, Inc.'s August share price decline after the messy phase 2 results of NBI-568 in schizophrenia patients is understandable, but the magnitude is not. Neurocrine is trading at slo
Data Support Positive Impact of INGREZZA in People With Huntington's Disease Chorea Findings Presented at the 2024 Annual Meeting of the Huntington Study Group SAN DIEGO , Nov. 7, 2024 /PRNewswire/ -
Neurocrine Biosciences to Participate at Investor Conferences in November
04:01pm, Tuesday, 05'th Nov 2024
2024 UBS Global Healthcare Conference on November 12 Stifel 2024 Healthcare Conference on November 18 Jefferies London Healthcare Conference on November 19 SAN DIEGO , Nov. 5, 2024 /PRNewswire/ -- Neu
Findings Presented at the 2024 Psych Congress Include Data From More Than 300 Patients SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from more
SAN DIEGO , Nov. 4, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) presented data from the long-term KINECT®-4 study demonstrating tardive dyskinesia remission in nearly 60% of par
Neurocrine Biosciences, Inc. (NBIX) Q3 2024 Earnings Call Transcript
03:11pm, Wednesday, 30'th Oct 2024
Neurocrine Biosciences, Inc. (NASDAQ:NBIX ) Q3 2024 Earnings Conference Call August 30, 2024 8:00 AM ET Company Participants Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Office
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
10:35am, Wednesday, 30'th Oct 2024
Although the revenue and EPS for Neurocrine (NBIX) give a sense of how its business performed in the quarter ended September 2024, it might be worth considering how some key metrics compare with Wall
